High-rolling investors have positioned themselves bearish on Novo Nordisk (NYSE:NVO), and it's important for retail traders to take note.This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in NVO often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Novo Nordisk. This is not a typical pattern.
The sentiment among these major traders is split, with 33% bullish and 55% bearish. Among all the options we identified, there was one put, amounting to $25,200, and 8 calls, totaling $430,150.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $145.0 for Novo Nordisk over the last 3 months.
Analyzing Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $100.0 to $145.0 over the preceding 30 days.
Novo Nordisk Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
| NVO | CALL | TRADE | BEARISH | 01/17/25 | $38.8 | $38.5 | $38.5 | $100.00 | $77.0K | 1.3K | 20 |
| NVO | CALL | SWEEP | BEARISH | 11/15/24 | $7.15 | $7.05 | $7.05 | $140.00 | $70.5K | 673 | 17 |
| NVO | CALL | TRADE | BULLISH | 01/16/26 | $32.3 | $30.95 | $31.8 | $120.00 | $63.6K | 507 | 20 |
| NVO | CALL | SWEEP | NEUTRAL | 10/18/24 | $3.05 | $2.83 | $2.91 | $145.00 | $59.6K | 400 | 208 |
| NVO | CALL | TRADE | BULLISH | 01/16/26 | $29.0 | $28.2 | $29.0 | $125.00 | $58.0K | 588 | 0 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo Nordisk's Current Market Status
- With a volume of 1,618,827, the price of NVO is down -1.05% at $133.88.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 65 days.
Professional Analyst Ratings for Novo Nordisk
In the last month, 3 experts released ratings on this stock with an average target price of $160.0.
- Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Novo Nordisk, targeting a price of $160.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with Benzinga Pro for real-time alerts.
高额投资者已将自己定位为看跌诺和诺德（纽约证券交易所代码：NVO），散户交易者注意这一点很重要。\ 这项活动今天通过Benzinga对公开期权数据的追踪引起了我们的注意。这些投资者的身份尚不确定，但是NVO的如此重大举措通常表明有人拥有特权信息。
今天，Benzinga的期权扫描仪发现了Novo Nordisk的9笔期权交易。这不是典型的模式。
这些主要交易者的情绪分歧，33％看涨，55％看跌。在我们确定的所有期权中，有一个看跌期权，金额为25,200美元，还有8个看涨期权，总额为430,150美元。
预计价格目标
考虑到这些合约的交易量和未平仓合约，在过去的3个月中，鲸鱼似乎一直将Novo Nordisk的价格定在100.0美元至145.0美元之间。
分析交易量和未平仓合约
评估交易量和未平仓合约是期权交易的战略步骤。这些指标揭示了Novo Nordisk在指定行使价下期权的流动性和投资者对Novo Nordisk期权的兴趣。即将发布的数据可视化了与诺和诺德的大量交易相关的看涨期权和未平仓合约的波动，在过去30天内，行使价范围从100.0美元到145.0美元不等。
过去 30 天的 Novo Nordisk 期权交易量和未平仓合约
发现的最大选择：
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | CALL | TRADE | BEARISH | 01/17/25 | $38.8 | $38.5 | $38.5 | $100.00 | $77.0K | 1.3K | 20 |
NVO | CALL | SWEEP | BEARISH | 11/15/24 | $7.15 | $7.05 | $7.05 | $140.00 | $70.5K | 673 | 17 |
NVO | CALL | TRADE | BULLISH | 01/16/26 | $32.3 | $30.95 | $31.8 | $120.00 | $63.6K | 507 | 20 |
NVO | CALL | SWEEP | NEUTRAL | 10/18/24 | $3.05 | $2.83 | $2.91 | $145.00 | $59.6K | 400 | 208 |
NVO | CALL | TRADE | BULLISH | 01/16/26 | $29.0 | $28.2 | $29.0 | $125.00 | $58.0K | 588 | 0 |
关于 Novo Nordisk
诺和诺德拥有全球品牌糖尿病治疗市场约三分之一的份额，是全球领先的糖尿病护理产品提供商。该公司总部位于丹麦，生产和销售各种人用和现代胰岛素、注射型糖尿病治疗药物（如 GLP-1 疗法）、口服抗糖尿病药物和肥胖疗法。Novo还有一个生物制药板块（约占收入的10％），专门研究血友病和其他疾病的蛋白质疗法。
诺和诺德的当前市场状况
诺和诺德的专业分析师评级
上个月，3位专家发布了该股的评级，平均目标价为160.0美元。
BMO Capital的一位分析师保持立场，继续对诺和诺德维持跑赢大盘的评级，目标价格为160美元。
坎托·菲茨杰拉德的一位分析师已将其评级下调至增持，将目标股价调整为160美元。
坎托·菲茨杰拉德的一位分析师谨慎地将其评级下调至增持，将目标股价定为160美元。
交易期权涉及更大的风险，但也提供了更高利润的潜力。精明的交易者通过持续的教育、战略贸易调整、利用各种指标以及随时关注市场动态来降低这些风险。使用 Benzinga Pro 了解诺和诺德的最新期权交易，获取实时提醒。
